

### AMENDMENTS TO THE CLAIMS

1. **(Currently amended)** An isolated human monoclonal antibody that binds to MCP-1 and comprises a heavy chain polypeptide having the sequence of SEQ ID NO.: 62.
2. **(Previously presented)** The antibody of Claim 1, further comprising a light chain polypeptide having the sequence of SEQ ID NO.:64.
- 3.-40. **(Cancelled)**
41. **(Currently amended)** An isolated antibody immobilized on an insoluble matrix, wherein the antibody is the antibody of Claim 1.
42. **(Withdrawn previously presented)** A method for assaying the level of monocyte chemo-attractant protein (MCP-1) in a patient sample, comprising:
  - contacting the anti-MCP-1 antibody of Claim 1 with the patient sample; and
  - detecting the level of MCP-1 in the patient sample.
43. **(Withdrawn)** A method according to Claim 42, wherein the patient sample is blood.
44. **(Currently amended)** A composition, comprising the antibody ~~or fragment thereof~~ of Claim 1, and a pharmaceutically acceptable carrier.
45. **(Withdrawn amended)** A method of effectively treating a neoplastic disease, comprising:
  - selecting an animal in need of treatment for a neoplastic disease; and
  - administering to said animal a therapeutically effective dose of the antibody of Claim 1.
46. **(Withdrawn amended)** The method of Claim 45, wherein said neoplastic disease is selected from the group consisting of: breast cancer, ovarian cancer, bladder cancer, lung cancer, glioblastoma, stomach cancer, endometrial cancer, kidney cancer, colon cancer, pancreatic cancer, and ~~prostrate~~ prostate cancer.
47. **(Withdrawn amended)** A method of effectively treating inflammatory conditions, comprising:
  - selecting an animal in need of treatment for an inflammatory condition; and
  - administering to said animal a therapeutically effective dose of the antibody of Claim 1.

48. **(Withdrawn)** The method of Claim 47, wherein said inflammatory condition is selected from the group consisting of: rheumatoid arthritis, glomerulonephritis, atherosclerosis, psoriasis, restenosis, autoimmune disease, and multiple sclerosis.

49. **(Cancelled)**

50. **(Cancelled)**

51. **(Currently amended)** An isolated human monoclonal antibody that binds to the sequence ISVQRLASYRRITSSK (SEQ ID NO.: 150).

52. **(Cancelled)**

53. **(Previously presented)** A method of manufacturing the antibody of Claim 1, comprising:

immunizing a mammal with a synthetic peptide of MCP-1;

recovering a lymphatic cell that expresses the antibody of Claim 1 from the immunized mammal; and

fusing the lymphatic cell with a myeloid-type cell to prepare a hybridoma cell that produces the antibody of Claim 1.

54. **(New)** The antibody of Claim 1, wherein said antibody is conjugated to a therapeutic agent.

55. **(New)** The antibody of Claim 54, wherein said therapeutic agent is a toxin.

56. **(New)** The antibody of Claim 55, wherein said toxin is an immunotoxin.

57. **(New)** The antibody of Claim 54, wherein said therapeutic agent is a chemotherapeutic agent.

58. **(New)** The antibody of Claim 57, wherein said chemotherapeutic agent is selected from the group consisting of taxol, doxorubicin, cis-platinum, and 5-fluorouracil.

59. **(New)** The antibody of Claim 54, wherein said therapeutic agent is a steroid.

60. **(New)** The antibody of Claim 54, wherein said therapeutic agent is a radioisotope.

61. **(New)** The antibody of Claim 60, wherein said radioisotope is selected from the group consisting of  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{15}\text{N}$ ,  $^{35}\text{S}$ ,  $^{90}\text{Y}$ ,  $^{99}\text{Tc}$ ,  $^{111}\text{In}$ ,  $^{125}\text{In}$ , and  $^{131}\text{I}$ .

62. **(New)** The antibody of Claim 51, wherein said antibody is conjugated to a therapeutic agent.

63. **(New)** The antibody of Claim 62, wherein said therapeutic agent is a toxin.

**Appl. No.** : **10/644,277**  
**Filed** : **August 19, 2003**

64. (New) The antibody of Claim 63, wherein said toxin is an immunotoxin.
65. (New) The antibody of Claim 63, wherein said therapeutic agent is a chemotherapeutic agent.
66. (New) The antibody of Claim 65, wherein said chemotherapeutic agent is selected from the group consisting of taxol, doxorubicin, cis-platinum, and 5-fluorouracil.
67. (New) The antibody of Claim 65, wherein said therapeutic agent is a steroid.
68. (New) The antibody of Claim 65, wherein said therapeutic agent is a radioisotope.
69. (New) The antibody of Claim 68, wherein said radioisotope is selected from the group consisting of  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{15}\text{N}$ ,  $^{35}\text{S}$ ,  $^{90}\text{Y}$ ,  $^{99}\text{Tc}$ ,  $^{111}\text{In}$ ,  $^{125}\text{In}$ , and  $^{131}\text{I}$ .
70. (New) The antibody of Claim 1, wherein said antibody neutralizes the activity of MCP-1.
71. (New) The antibody of Claim 41, wherein said antibody neutralizes the activity of MCP-1.
72. (New) The antibody of Claim 51, wherein said antibody neutralizes the activity of MCP-1.
73. (New) The antibody of Claim 1, wherein said antibody binds to MCP-1 with a dissociation constant ( $K_D$ ) of approximately 3.0 pM.
74. (New) The antibody of Claim 73, wherein said dissociation constant is 3.3 pM.
75. (New) The antibody of Claim 41, wherein said antibody binds to MCP-1 with a dissociation constant ( $K_D$ ) of approximately 3.0 pM.
76. (New) The antibody of Claim 75, wherein said dissociation constant is 3.3 pM.
77. (New) The antibody of Claim 51, wherein said antibody binds to MCP-1 with a dissociation constant ( $K_D$ ) of approximately 3.0 pM.
78. (New) The antibody of Claim 77, wherein said dissociation constant is 3.3 pM.
79. (New) An isolated human monoclonal antibody binding fragment that binds to MCP-1 and comprises a heavy chain polypeptide having the sequence of SEQ ID NO.: 62.
80. (New) The antibody binding fragment of Claim 79, further comprising a light chain polypeptide having the sequence of SEQ ID NO.: 64.
81. (New) The antibody binding fragment of Claim 79, wherein said binding fragment is selected from the group consisting of Fab, Fab', F(ab')<sub>2</sub>, and F<sub>v</sub>.

**Appl. No.** : **10/644,277**  
**Filed** : **August 19, 2003**

82. **(New)** The antibody binding fragment of Claim 79, wherein said fragment is conjugated to a therapeutic agent.